Form 4: Processa Pharmaceuticals Grants Over 1.3 Million Restricted Stock Units to Chief Administrative Officer

Processa Pharmaceuticals, Inc. has granted 1,366,046 restricted stock units to Chief Administrative Officer Wendy Guy, aligning executive incentives with long-term company performance.

Summary

• Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, Inc. (PCSA), was granted 1,366,046 Restricted Stock Units (RSUs).
• The grant occurred on July 24, 2025, under the company's 2019 Omnibus Incentive Plan.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs will vest one-third on January 1, 2026, and one-thirty-sixth each month thereafter, fully vesting by January 1, 2028.
• A significant portion, 1,349,245 shares, is subject to stockholder approval of the revised Omnibus Plan.
• Following this transaction, Wendy Guy beneficially owns 1,376,478 derivative securities.

Sentiment

Score: 6

Explanation: The grant of RSUs to a key executive is generally a positive sign of aligning interests and retaining talent, but the contingency on stockholder approval and potential future dilution are minor considerations.

Positives

• Granting of Restricted Stock Units to a key executive like the Chief Administrative Officer aligns management's interests with long-term shareholder value.
• The multi-year vesting schedule encourages long-term retention and performance from the executive.

Negatives

• A substantial portion of the RSU grant (1,349,245 shares) is contingent on stockholder approval of the revised Omnibus Plan, introducing a condition to the full realization of the grant.
• The conversion of RSUs into common stock will result in dilution for existing shareholders upon vesting.

Risks

• The full realization of 1,349,245 RSUs is contingent upon stockholder approval of the revised 2019 Omnibus Incentive Plan, meaning the grant could be partially or fully rescinded if approval is not obtained.
• Future dilution of common stock will occur as the 1,366,046 Restricted Stock Units vest and convert into shares.

Future Outlook

The future outlook indicates that a significant portion of the RSU grant is contingent on stockholder approval of the revised 2019 Omnibus Incentive Plan, and the RSUs will vest over a period extending to January 1, 2028, aligning executive incentives with long-term company performance.

Industry Context

This filing is a standard disclosure of executive equity compensation, a common practice across industries, particularly in biotechnology and pharmaceuticals, to attract and retain key talent and align their interests with long-term company performance.

Comparison to Industry Standards

• Executive equity grants, particularly Restricted Stock Units with multi-year vesting schedules, are a standard compensation practice in the biotechnology and pharmaceutical sectors.
• The size of the grant (over 1.3 million units) for a Chief Administrative Officer would need to be benchmarked against similar roles in companies of comparable market capitalization and stage of development within the industry to assess its relative scale, though specific comparable companies or projects are not detailed in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution upon conversion of RSUs to common stock, but also improved alignment of executive incentives with long-term company performance.
• Employees: The grant under the Omnibus Incentive Plan suggests a framework for broader employee equity compensation, potentially boosting morale and retention.

Next Steps

• Seek stockholder approval for the revised 2019 Omnibus Incentive Plan.
• Continue the vesting process for the granted Restricted Stock Units according to the specified schedule.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Form 4, Equity Grant, Omnibus Incentive Plan, Corporate Governance